Dysfunctional Activation of Neurotensin/IL-8 Pathway in Hepatocellular Carcinoma Is Associated with Increased Inflammatory Response in Microenvironment, More Epithelial Mesenchymal Transition in Cancer and Worse Prognosis in Patients

Jinpu Yu\textsuperscript{1,2}, Xiubao Ren\textsuperscript{2}, Yongzi Chen\textsuperscript{3}, Pengpeng Liu\textsuperscript{1,2}, Xiinyin Wei\textsuperscript{3}, Hui Li\textsuperscript{2}, Guoguang Ying\textsuperscript{3}, Kexin Chen\textsuperscript{4}, Hans Winkler\textsuperscript{1}, Xishan Hao\textsuperscript{1*}

\textsuperscript{1} TMUCIH-JnJ joint laboratory, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China, \textsuperscript{2} Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China, \textsuperscript{3} Laboratory of Cancer Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China, \textsuperscript{4} Department of Epidemiology, Tianjin Medical University Cancer Institute & Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

Abstract

\textbf{Aim}: To investigate the role of neurotensin (NTS) in hepatocellular carcinoma (HCC) sub- grouping and the clinical and pathological significance of activation of NTS/IL-8 pathway in HCC.

\textbf{Methods}: The genome-wide gene expression profiling were conducted in 10 pairs of cancer tissues and corresponding normal adjacent tissues samples using Affymetrix GeneChip\textsuperscript{®} Human Genome U133 Plus 2.0 microarray to screen differentially expressing genes and enrich dysfunctional activated pathways among different HCC subgroups. The levels of NTS protein and multiple inflammation and epithelial mesenchymal transition (EMT) related proteins, including IL-8, VEGF, MMP9, CD68, E-Cadherin, β-Catenin and Vimentin were examined in 64 cases of paraffin-embedded HCC samples using immunohistochemistry (IHC) staining method. The clinical outcome and overall survival (OS) were compared.

\textbf{Results}: A subgroup of HCC characterized by up-regulated NTS expression was accompanied by up-regulated inflammatory responses and EMT. The direct interaction between NTS and IL-8 was identified by pathway enrichment analysis. Significantly increased IL-8 protein was confirmed in 90.91% of NTS+ HCC samples and significantly positively correlated to the levels of NTS protein in cancer tissues (P = 0.036), which implied activation of NTS/IL-8 pathway in HCC. The levels of VEGF and MMP9 correlated with co-expression of NTS and IL-8. Increased infiltration of CD68+ macrophages and more cancer cells displaying EMT features were found in NTS+IL-8+ samples. The co-expression of NTS and IL-8 in cancer significantly correlated with the clinical outcomes, as the mortality rate of NTS+IL-8+ HCC patients is 2.5-fold higher than the others after the surgery (P = 0.022). Accordingly, the OS of NTS+IL-8+ HCC patients significantly decreased who are under a higher hazard of death at an expected hazard ratio (HR) of 3.457.

\textbf{Conclusion}: Dysfunctional activation of the NTS/IL-8 pathway was detected in HCC which is associated with increased inflammatory response in microenvironment, enhanced EMT in cancer, and worse prognosis in HCC patients.

Introduction

Hepatocellular carcinoma (HCC) is one of the most commonly diagnosed cancers with the mortality rate ranking at the third worldwide \cite{1}. Due to the high frequency of local metastasis and recurrence after surgery, the 5-year survival rate in HCC patients is less than 5%. Therefore, identification of biomarkers significantly relate to invasion and metastasis of HCC cells and elucidation of the molecular mechanisms for developing novel therapeutic approaches are essential for better HCC treatment.

Inflammation represents a major pathologic factor for malignancies in the occurrence and progression of HCC. Persistent
infections of hepatitis viruses and chronic cirrhosis induced by non-viral factors, such as alcohol and inherited metabolic disease in liver, have been shown to lead to long-lasting infiltration of inflammatory cells and formation of HCC [2]. According to the “immune-editing” theory [3], several types of inflammatory cells in cancers, including tumor associated macrophages (TAMs) [4], regulatory dendritic cells (DCs) [5], polymorphonuclear neutrophils (PMNs) [6] and mast cells [7], produce inflammatory cytokines and chemokines that promote the growth and metastasis of cancers [8]. In addition to infiltrating immunocytes, it has been reported that multiple cytokines produced by malignant cells contribute to the development and maintenance of a local inflammatory microenvironment [9,10]. However, concrete mechanisms regulating inflammation-related development and progression of HCC are still unclear.

Considering the complexity of hepato-carcinogenesis, a large number of genes might be involved in inflammation-related development and progression of HCC. Therefore, high-dimensional array technologies and analytical high-throughput genome-wide gene expression profiling may provide a systematic and efficient approach to discover new candidate genes which could serve as potential therapeutic targets or predictive biomarkers for HCC patients [11]. Currently, a large number of microarray studies conducted in HCC have shown different outcomes, including generation of characteristic gene signatures for molecular classification of HCC and development of novel predictors for metastasis, recurrence and outcome of HCC [12,13]. However, because of the low reproducibility and limited predictive accuracy of each reported system in different cohorts, the ongoing challenge is to identify and characterize clinically relevant genes that can serve as classification biomarkers and therapeutic targets simultaneously based on known pathway alterations in HCC.

Therefore, in this study we conducted comprehensive expression analysis of a total of 41 cases of genome-wide gene expression profiling data from HCC tissues (10 from in-house database, 31 from the public database GEO). We used a specific, unsupervised filtering method—Spectral Map Analysis (SMA) to distinguish subgroups with different genetic features among HCC samples and screen for prevalent candidate genes differentially expressed in different subgroups. In order to demonstrate the clinical significance of target genes, we performed immunohistochemistry (IHC) staining to determine their expression in 64 cases of primary HCC tissues and evaluated the relevance among the protein expression, clinical features, and the prognosis of these patients. We found a distinct HCC subgroup characterized by increased NTS expression which was accompanied by increased inflammatory responses and up-regulated epithelial mesenchymal transition (EMT) related signal pathways. Dysfunctional activation of the inflammation-related NTS/IL-8 pathway was identified by pathway enrichment analysis and IHC staining method, in which synchronous increase of NTS and IL-8 in cancer cells was detected in 90.91% NTS+ HCC samples. Co-expression of NTS and IL-8 positively correlated with increased expression of VEGF and MMP9 in cancer. Increased infiltration of CD68+ TAMs and higher number of cancer cells displaying EMT-related features were found in NTS+IL-8+ samples. Furthermore, co-expression of NTS and IL-8 in HCC significantly correlated with worse prognosis and shorter survival in patients after surgery. These results implied that dysfunctional activation of NTS/IL-8 pathway in HCC associates with increased inflammatory response in microenvironment, enhanced EMT in cancer and worse prognosis of patients. Thus, intervention of NTS/IL-8 pathway may be proposed as a novel strategy to reducing local inflammation and intervening cancer invasion which had the potential to serve as a promising predictive biomarker and/or therapeutic target for HCC.

**Materials and Methods**

**Patient Information**

A total of 64 cases of HCC patients who were treated with partial liver resection surgery at the Department of Hepatobiliary Oncology of Tianjin Cancer Institute & Hospital from November 2007 to July 2009 were enrolled in this study. These patients included 38 males and 6 females, with a mean age of 54.44 years (range: 33 to 71 years). The patients were pathologically diagnosed with HCC at histological grade I (n = 4), grade II (n = 36), and grade III (n = 24), and classified as stage I (n = 8), stage II (n = 44), and stage III (n = 12). No prior treatments (including chemotherapy or radiotherapy) were conducted before the liver resection surgery. Fresh tissue samples from 10 patients, including primary tumors and normal adjacent tissues, were collected and immediately stored at −80°C for microarray analysis. These 10 patients...
Raw data were obtained using the GCOS software and analyzed using Bioconductor 2.4. GeneChip Human Genome U133 Plus 2.0 microarray chips (Affymetrix, Santa Clara, CA, USA) were used for gene expression profiling. The chips were washed in the GeneChip Fluidics Station (Affymetrix, Santa Clara, CA, USA) and subsequently scanned using the GeneChip Scanner 3000 (Affymetrix, Santa Clara, CA, USA). The raw data were obtained using the GCOS software and analyzed using R2.9.0 software and Bioconductor 2.4.

Microarray Data Generated From the in-house Samples

RNA (250 ng) was reverse transcribed into cRNA using GeneChip® 3′ IVT Express Kit (Affymetrix, Santa Clara, CA, USA) and purified using BioMek® Fx workstation (Beckman Coulter, CA, USA). Afterwards, the purified cRNAs were fragmented into 35 to 200-nt long fragments and hybridized to the GeneChip® Human Genome U133 Plus 2.0 microarray chips (Affymetrix, Santa Clara, CA, USA) using standard protocols. The chips were washed in the GeneChip Fluidics Station (Affymetrix, Santa Clara, CA, USA) and subsequently scanned using the GeneChip® Scanner 3000 (Affymetrix, Santa Clara, CA, USA). Raw data were obtained using the GCOS software and analyzed using R2.9.0 software and Bioconductor 2.4.

Microarray Data Downloaded From the Gene Expression Omnibus (GEO) Database

Thirty-one cases of gene expression profiling data of Asian HCC patients on the identical Affymetrix HGU133 plus 2.0 arrays were obtained from the Gene Expression Omnibus (GEO) database: GSE2109, GSE6465 [14], and GSE6222 [15].

Quality Control of the Microarray Data

After the raw data were achieved, a quality control (QC) of microarray data was conducted to evaluate the eligibility of the raw data. The QC test of 20 cases of HCC samples and according normal adjacent tissues was conducted using the SimpleAffy package of Bioconductor 2.4 in which normal RNA degradation, comparable distribution of signal intensities, and overlapped hybridization signals of specific control genes were confirmed (Figure 1A–C).

Bioinformatics Analysis of the Microarray Data

Raw data of 10 pairs of in-house samples was preprocessed using GC-RMA method to conduct background correction and normalization. Summarization was done with median polish, using the hgu133plus2entrezg.13.0.0 CDF [16] and the preprocessed expression dataset (eSet) were filtered on I/NI calls [17]. All informative genes of 20 cases of experimental hepatic samples (10 cancer tissue samples and 10 adjacent normal tissue samples) were collected to generate corresponding spectral maps to distinguish the most significant diversity of gene expression profiles among samples. Spectral Map Analysis (SMA) is a multivariate projection method that allows reduction of the complexity of high dimensional data, in which a bi-plot is created by the first two principal components displays the maximal separation of both the transcripts and the samples which provides means to visually

A subgroup of NTS high expressing HCC is identified from the gene expression profiling data of 10 pairs of in-house HCC tissues and corresponding adjacent normal tissues. Different subgroups of HCC samples were separated by the unsupervised filtering analysis SMA algorithm. In SMA, the sample names were shown in colorful squares. The genes were depicted in black circles and the size of the circle reflected the mean expression level of the gene over all samples. The subgroups of samples were separated using rectangles in different color, and the characteristic gene signature of certain subgroup was included in the corresponding rectangle as well. A) In Figure 2A, 3 subgroups of 20 cases of samples with distinct expression profiling features are separated along the X(PC1) axis and Y(PC2) axis. PC1 contributes 47% of variability and PC2 contributed 18% of variability in the gene expression profiling data of all 20 samples. The most significantly differentially expressed genes in each subgroup were listed in the same direction and included in the corresponding rectangle as well. Two HCC samples (c-13426 and c-13732, red rectangle) were distinguished from the others 8 cases of HCC samples (blue rectangle) and 10 cases of corresponding adjacent normal tissues (green rectangle) in the spectral map. NTS (red arrow), KRT19 and MMP12 were screened out as highly expressed genes in these 2 samples. B) The SMA was repeated in 10 cases of HCC samples which were divided into 2 subgroups scattering around the central marker “+”. Two HCC samples (c-13426 and c-13732, red rectangle) were separated out of the others 8 cases of HCC samples (blue rectangle), in which the NTS gene showed relatively higher expression in these 2 samples (red arrow). C). Quantity of NTS expression at mRNA level in the HCC tissues and adjacent normal tissues. The green plots represent cancer tissue samples, and the red plots represent normal adjacent tissue samples.

doi:10.1371/journal.pone.0056069.g002
inspect and identify clusters of transcripts and/or subjects in the data [18]. In order to increase the credibility of results, other 31 cases of raw data of primary hepatic cancer tissue samples based on the same Affymetrix chip platform were downloaded from GEO and integrated with primary in-house raw data to conduct SMA. Subgroups consisted of different cluster of HCC samples were separated in SMA and differentially expressed genes in each subgroup were identified using the Linear Models for Microarray Data algorithm (LIMMA) [19]. For the spectral map and LIMMA analysis, the Bioconductor A4 package [20] was used. The criteria for differential expression were defined as a difference greater than 3 fold and \( P < 0.05 \). The top 150 differentially expressed genes of the different HCC subgroups were separately entered into MetaCore\textsuperscript{TM} 2.5 (GeneGo, Carlsbad, CA), Pathway Studio\textsuperscript{H} 6.0 (Ariadne Genomics, Rockville, MD, USA) and IPA\textsuperscript{H} 1.0 (Ingenuity Systems, Redwood City, CA, USA) software to screen for the most correlative signaling pathways involved in subgrouping and to construct a visual regulatory network [21].

**Pathological Validation of Differentially Expressed Genes**

The expression and cell location of differentially expressed genes *in situ* were examined using IHC staining method among 64 cases of HCC cancer tissues and corresponding normal adjacent tissues. The inflammatory response in microenvironment was evaluated by comparing the expression of multiple inflammation-related proteins (including chemotaxin IL-8, angiogenic growth factors VEGF and matrix metalloproteinase MMP9) and the number of infiltrated CD68\textsuperscript{+} TAMs. The EMT phenotypic alteration of HCC cells was determined by loss of E-Cadherin on membrane and accumulation of \( \beta\)-Catenin and Vimentin in cytoplasm.

For IHC, samples were heated for 0.5 h at 56°C, deparaffinized in xylene and rehydrated through graded alcohol. Antigens were retrieved by heating in citrate buffer (pH 6.0) for 20 minutes. Endogenous peroxidase activity was quenched in a bath of methanol and hydrogen peroxide for 30 minutes. All samples were incubated overnight at 4°C with mouse anti-human NTS, IL-8, VEGF, MMP9, CD68, E-Cadherin, \( \beta\)-Catenin and Vimentin monoclonal antibodies (Santa Cruz, CA, USA) at concentrations of 1:1000, and a biotinylated secondary antibody (goat anti-mouse IgG, Santa Cruz, CA, USA) labeled with streptavidin-horseradish peroxidase (HRP) using a DAB staining kit (Maixin Biotechnology, Fuzhou, China). For negative control, the primary antibody was substituted with mouse isotype IgG1. Positive cells were stained brownish yellow in the cytoplasm or on the cell membrane. An Olympus BX51 microscope was used for image acquisition.

Five representative high-power fields (400 x magnification) for each tissue section were selected for histology evaluation. For each protein, two parameters: Positive Rate (PR) and Staining Intensity (SI) were used to describe the expression based on the extensity and intensity of positively stained cells in the samples. PR is the percentage of positively stained cells in cancer tissues, in which the...
10% was defined as negative (scored as 0), 11–30% as positive of low frequency (scored as 1), 31–60% as positive of medium frequency (scored as 2), and >60% as positive of high frequency (scored as 3). SI is the ranked staining intensity of positively stained cells in HCC samples, which ranged from 0 to 3 and represented negative, dim positive, mediate positive and strong positive. Since the expression of certain protein was comprehensively evaluated based on both extensity and intensity, the sum of both parameters gave the final scores of each protein marker in each HCC sample, in which the final score ≤ 4 was defined as low/negative expression, and the final score ≥ 4 was defined as high expression.

### Table 1. Pathways enriched from differentially expressed genes between HCC tissues of high and low NTS expression by PathwayStudio™.

| Pathways enriched by Pathway Studio | Number of overlapping genes | Overlapping genes                                                                 | P value  |
|-------------------------------------|-----------------------------|-----------------------------------------------------------------------------------|----------|
| **Down-regulated genes**            |                             |                                                                                   |          |
| Lipid metabolic process             | 48                          | CYP7A1, ACOX2, EHADH, INSIG1, LURP5, HSD17B6, PLTP, HPGD, ACOT12, CYP3A4, PO1N, TTPA, ACSL5, HSD11B1, ACA2, ACSL6, LIPA, SLC27A5, PLA1A, HADH, AP0C4, BAAT, RODH16, AP0E, ACSM5, ALDH3A2, ACSM3, HSD17B10, SLC27A3, SULT2A1, ABCB4, THRSP, SRD5A2, DGAT2, PLC2, ACSL1, AKR1D1, ECH1, PMVK, ACADSB, AADAC, ACADL, FADS1, AP0B, ACSM1, ECHDC2, CYF7P1, MBTPS2 | 3.184e−22 |
| Fatty acid metabolic process        | 27                          | ACSM5, FABP4, ACOX2, PCCA, EHADH, GPMAM, ACSM3, SC4MOL, CYP4A11, HPGD, ACOT12, SLC27A3, CYB5A, CRYL1, ACSL5, HAO2, ACSL1, ACA2, ACSL6, ECH1, SLC27A5, ACADSB, ACADL, HADH, BAAT, ACSM1, ECHDC2 | 1.623e−20 |
| Steroid metabolic process           | 14                          | CYP7A1, INSIG1, HSD17B6, AKR1B10, SULT2A1, OSBPL6, HSD11B1, CYP3A5, AKR1D1, NR1I2, OSBPL3, AP0B, CYF7P1, MBTPS2 | 1.932e−8  |
| Aldehyde metabolic process          | 6                           | ALDH3A2, AKR7A3, AKR1B10, ALDH7A1, ADH4, ALDH1A1 | 1.547e−7  |
| Blood coagulation                   | 13                          | SERPINC1, F9, F5, F7, LM1A1, SERPIND1, F11, PLGLPA, COCH, SERPINE1, F13B, F10 | 2.841e−1  |
| Amino acid metabolic process        | 10                          | SLC7A5, SDSL, GLUD1, TAT, HMGCL, MATTA, SLC7A2, OTCA5N5 | 1.296e−6  |
| Cholesterol metabolic process       | 10                          | CYP7A1, INSIG1, CYP27A1, PON1, TNFSF4, NR0B2, AP0B, CYF7P1, MBTPS2 | 1.535e−5  |
| Biotin metabolic process            | 3                           | PCCA, MCC1C1, BTD | 1.954e−5  |
| Bile acid metabolic process         | 5                           | ACOX2, AMACR, SLC27A5, AKR1C1, BAAT | 4.794e−5  |
| Acyl-CoA metabolic process          | 6                           | EHHADH, ACOT12, SLC27A3, GLYAT, HMGCL, ACSL6 | 5.458e−5  |
| **Up-regulated genes**              |                             |                                                                                   |          |
| Inflammatory response               | 21                          | CXCL2, CCL16, CCL5, KNG1, CCR5, TNFSF4, NFKB1Z, ATN1, IL1B, BLNK, CCL25, CCL8, SPP1, CD10, EPHB2, EVL, AOX1, ALOX5AP, CYP4F11, CRP, CYP4F2 | 1.848e−4  |
| Response to reactive oxygen species | 6                           | CAT, ALDH3A2, SERPINE1, AP0E | 7.370e−4  |
| Acute-phase response                | 6                           | CEBPA, LBP, ASS1, HPR, CRP, BAAT | 7.567e−4  |
| Complement activation               | 7                           | MASP2, C4BPA, C8B, CRP, MBL2, C7, C6 | 9.159e−4  |
| Chemotaxis                          | 11                          | CXCL2, CCL15, CCL16, CCL5, SERPIND1, CCR5, CSAR1, IL8, CCL25, CLEC2, CCL8 | 0.002178 |
| Immune response                     | 34                          | CXCL2, MASP2, COLEC12, CCL14, CCL16, CCL5, C4BPA, CCR5, TNFSF4, APOB, FGR2B, IL6R, CSAR1, IL8, DQ1A, TCF19, MBL2, AZGP1, IL8, CCL25, CCL8, IER3, CCL15, DPP4, IGK, HAMP, HNF4D, FGR3B, RGS1, IGHC, CRBP, BG5P, AFPG, HGF | 0.008114 |
| Leukocyte migration                 | 11                          | ICAM1, I6, MMP9, PECAM1, VEGFA, ITGA2, THBS1, ADAM10, SELP, ITGB2, SELE | 0.01 |
| Angiogenesis regulation             | 9                            | Rhob, VASH2, AGGF1, AMOT, ANGPTL3, BTG1, ITGB2, IL1B, HIF1A | 0.01 |
| Cell adhesion                       | 13                          | ADAM9, AGT, CD44, CDK5, COL3A1, COL5A3, CTGF, ECM1, CTNMB1, FN1, ITGA3, ITGA6, RHOA | 0.01 |
| Collagen fibril organization        | 8                            | COL11A1, COL1A1, COL2A1, COL3A1, COL5A3, SERP1NH1, TGFB2, TGFB1 | 0.01 |

doi:10.1371/journal.pone.0056069.t001

High NTS in HCC Is Associated with Tumor Invasion

**Expression of NTS mRNA in 40 HCC samples**

[A.]

**Sample ID**

[B.]

**PC1 25%**

[C.]

**D.**

**E.**

1. Cell adhesion_ECM remodeling
2. Cell adhesion_Chemokines and adhesion
3. Bone metastases in Prostate Cancer
4. Cell adhesion_Cell-matrix glycoconjugates
5. Development_WNT signaling pathway, Part 2
6. Transcription targets of Androgen receptor involved in Prostate Cancer
7. Stromal-epithelial interaction in Prostate Cancer
8. Cytoskeleton remodeling_Keratin filaments
9. Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling
10. Transcription_Role of AKT in hypoxia induced HIF 1 activation
and a forward stepwise procedure to screen independent analysis was performed using the Cox proportional hazard model. The cumulative survival was determined by the Kaplan-Meier between HCC samples expressing different levels of NTS and IL-MMP9, CD68, E-Cadherin, unpaired T test was used to compare the difference of VEGF, correlations between the protein levels of NTS and IL-8. The order test and linear regression analysis was used to assess the stage and clinical outcome after surgery. The Spearman’s rank-divided into different groups according to gender, age, status of compare PRs and SIs among 64 cases of cancer tissues which were statistically significant differences in expression of NTS expression in 40 cases of integrated microarray data composing of 9 cases of cancer tissue, and activation of HIF-1 mediated EMT in HCC cells (data not shown).

### Results

A Subgroup of NTS High-expressing HCC is Identified Using Unsupervised Filtering Analysis of 20 Cases of Microarray Data from in-house Fresh Tissues

Using SMA, different subgroups of samples were separated according to the diversity of gene expression profiles of all 20 samples. In this case, all samples were divided into different subgroups based on the central marker “+”, and the most significantly differentially expressed genes in the certain subgroup of samples were listed in front of the certain subgroup which are considered as potential signatures for the separation of each subgroup from the other samples. The sample names were shown in colorful squares. The genes were depicted in black circles and the size of the circle reflected the mean expression level of the gene over all samples. The subgroups of samples were separated using rectangles in different color, and the characteristic gene signature of the certain subgroup was included in the corresponding rectangle as well (Figure 2A-B). Here, microarray data from 20 cases of experimental samples (10 cancer tissues and normal tissues) were enrolled to conduct SMA. In Figure 2A, 3 subgroups with distinct expression profiling features are separated along the X(PC1) axis and Y(PC2) axis. PC1 contributes 47% of variability with distinct expression profiling features are separated along the X(PC1) axis and Y(PC2) axis. PC1 contributes 47% of variability in the gene expression profiling data of all 20 samples. All cancer samples were separated from the normal adjacent tissue samples (green rectangle) on the different side of the spectral map, and two HCC samples (c-13426 and c-13732, red rectangle) were distinguished from the other cancer samples (blue rectangle), as opposed to two samples (c-13426 and c-13732, red rectangle) that cluster on the right. Among the top 10 differentially expressed genes between subgroups, the NTS gene showed relatively higher expression in c-13426 and c-13732 (red arrow, Figure 2B).

Therefore, the expression of NTS in these hepatic cancer samples (green plots) as well as the corresponding adjacent normal tissues (red plots) was examined at the RNA level (Figure 2C). The result reveals that NTS is over-expressed in the two liver cancer samples (c-13426 and c-13732) compared to the other 8 HCC samples and all adjacent normal tissue samples. We therefore grouped the carcinoma samples according to their NTS expression: the high-NTS-expression group (c-13426 and c-13732) and low-NTS-expression group (c-10665, c-13607, c-13701, c-14414, c-14544, c-15067, c-16220, and c-16294). Up-regulated NTS Gene Expression is Correlated to Activation of Inflammation and EMT-related Pathways after Pathway Enrichment

LIMMA analysis was used to identify a total of 1274 genes that were significantly differentially expressed between the NTS high and low expressing samples (P<0.05, Log FC >1.5; Fig. 3). When compared to the NTS low-expressing group, 579 genes were up-regulated and 695 genes were down-regulated in the 2 NTS high-expressing samples (red box in Fig. 3). Hyper-geometric pathway enrichment analysis conducted in Pathway Studio® showed that the genes with down-regulated expression are mainly involved in coagulation and lipid metabolism, whereas those with up-regulated expression contribute to inflammation-related biological progresses, including the remodeling of the extracellular matrix (ECM), cell adhesion, leukocyte migration, and angiogenesis (Table 1). Additional pathway enrichment analysis in MetaCore™ and IPA® confirmed the finding that the high NTS expression was closely related to inflammation-related pathways, including hepatic fibrosis/hepatic stellate cell activation, ECM remodeling, chemokines and adhesion, regulation of actin-based motility in the HCC tissue, and activation of HIF-1α and the Wnt/β-catenin-mediated EMT in HCC cells (data not shown).
Figure 5. All significantly differentially expressed genes between high and low NTS samples were put into Pathway Studio® to screen the candidates that were regulated by or interacted with NTS. The NTS/IL-8 pathway, a predominant inflammation-related pathway in colorectal carcinogenesis was distinguished. A). Up-regulated NTS expression closely correlated with increase of multiple inflammatory molecules. B). Direct interaction between NTS and chemotaxin IL-8 was confirmed. doi:10.1371/journal.pone.0056069.g005
A Subgroup of HCC High Expressing NTS was Confirmed in the Expanded Pool of 40 Microarray Data and Accompanied with Significantly Up-regulated Inflammation-related Pathways

To further confirm our findings, we supplemented our in-house gene expression raw data with public profiling data of HCC tissues in Asian patients from the Gene Expression Omnibus (GEO) (GSE2109, GSE6222 and GSE9843), yielding 31 evaluable cancer samples. We integrated these 31 cases of raw data with the 10 primary cases of in-house data to conduct data processing and finally generated a qualified eSet of 40 cases (1 in-house sample was deleted for high batch effect). NTS was found to be elevated in 10 samples (1–13426, 1–13732, 2–263, 4–3.3, 5–248696, 5–248697, 5–248712, 5–248724, 5–248727, 5–248728, red box in Fig. 4B–D) as compared to the other 30 samples (Fig. 4A). SMA was conducted to distinguish clusters of transcripts and/or subjects in 40 microarray data. Similar to previous observation, the 10 samples with high NTS expression clustered together on the left side and the remaining 30 samples with low NTS expression on the right side of the unfiltered spectral map, and NTS was shown as one of the top 20 differentially expressed genes between these 2 clusters (Fig. 4B). This result indicates that NTS is a pivotal biomarker to distinguish different subsets of HCC samples of variable transcriptional features. Therefore, LIMMA analysis was performed to identify the differentially expressed genes between 2 clusters of samples with different expression level of NTS in which 457 genes were screened out, including 166 up-regulated genes and 291 down-regulated genes ($P<0.05$, log fold change ($\log FC$) $>1.5$, Fig. 4C).

Afterwards, 10 cases of normal adjacent tissues were integrated with 40 cases of tumor tissues to repeat the LIMMA analysis using NTS as the exclusive subgrouping factor. A list of 123 commonly up-regulated genes in high-NTS samples was generated from all 49 cases of samples which can distinctively distinguish NTS over-expressing cancer samples from the low expressing samples in the heat map (blue box in Fig. 4D). Therefore, the 123 genes were inputted into the MetaCore™ and IPA® application software to enrich possible pathways affected by NTS and demonstrated that inflammation-related pathways, including ECM remodeling, chemotaxis and adhesion, cell-matrix glycol-conjugates, stromal-epithelial interaction and cytoskeleton remodeling were up-regulated in NTS-overexpressing tissues (Fig. 4E). Furthermore, 2 invasion-related pathways: HIF-1α signaling and Wnt/β-catenin signaling were up-regulated in NTS over-expressing tissues (Fig. 4F). Pathways enrichment analysis confirmed the finding that high NTS expression was closely related to the development of inflammatory response in microenvironment and partly associated with increased migration and invasion of tumor cells.
For further analysis, we imported all significantly differentially expressed genes between NTS high and low expressing samples into Pathway Studio to screen the candidate genes that were regulated by or interacted with the NTS gene [22]. The direct interaction between NTS and IL-8 protein, defined as the NTS/IL-8 pathway, has been reported to induce chronic inflammation in colorectal disease and play a pivotal role in the development and progression of multiple cancer types except HCC [23–26] (Fig. 5A–B). Since IL-8 is a potent pro-inflammatory chemotaxis cytokine that directly regulates cell migration, angiogenesis and tumor invasion, we hypothesized that NTS promotes inflammation via an IL-8 dependent pathway.

Therefore, the expression of NTS and IL-8 protein in HCC was detected in 64 cases of primary HCC tissues and corresponding normal adjacent tissues using IHC staining method. We found that
the frequency of NTS expressing tissues among all HCC samples was 17.19% (11/64). The NTS positive staining cells are exclusively HCC cells, in which brown-yellow particles were observed in cytoplasm (red arrowhead, Fig. 6A). No positive staining was observed in normal adjacent tissues. The average PR among 11 positive samples is (50.00 ± 11.62)% and the average SI is 2.91 ± 0.3, which implied the expression of NTS in positive cancer tissues is relatively extensive and strong though the frequency of positive cancer tissues is relatively low. Consistently, brown-yellow particles were observed in cytoplasm of IL-8 positively stained HCC cells (red arrowhead, Fig. 6B). The frequency of IL-8 expressing tissues among all HCC samples was 54.69% (35/64), but the frequency of IL-8 expressing tissues in NTS positive samples is much higher, 90.91% (10/11), which implied that most of NTS positive HCC cells co-expressed IL-8.

We compared the expression and distribution of IL-8 protein between NTS high expressing (NTS+) samples and NTS low-expressing (NTS−) samples. The average PR of IL-8 among 11 cases of NTS+ samples is (50.91 ± 13.57)% significantly higher than that of (31.42 ± 29.39)% among NTS− samples (P = 0.036), which implied that the expression of IL-8 was up-regulated in NTS high expressing HCC tissues. Furthermore, a scatter plot was generated to display the correlation between NTS and IL-8 protein levels in 64 samples using the curve estimation method in Regression Analysis. It’s demonstrated that the PRs of IL-8 significantly positively correlated to the PRs of NTS in cancer cells with a linear regression equations of Y = 28.213 + 0.456X (Y: PRs of IL-8; X: PRs of NTS) (R = 0.316, P = 0.011, Fig. 6C). Therefore, the synchronous increase of NTS and IL-8 proteins in 15.63% (10/64) HCC samples implied dysfunctional activation of the NTS/IL-8 pathway in a part of HCC.

Co-expression of NTS and IL-8 is Associated with Increased Inflammatory Response in Microenvironment and Enhanced EMT in Cancer Cells

In order to determine if co-expression of NTS and IL-8 (NTS+IL-8+) in HCC tissues correlates with the development of a local inflammatory response in microenvironment, the expression of VEGF and MMP9 proteins, as well as infiltration of CD68+ TAMs were studied among 64 cases of primary HCC tissues and corresponding normal adjacent tissues. The positive rate of VEGF in cancer was 48.44% (31/64, Fig. 6D) and the positive rate of MMP-9 was 45.31% (29/64, Fig. 6E). We then compared the expression of both protein markers between NTS+ samples and NTS− samples. The average PR of MMP9 in NTS+ samples is (49.09 ± 25.57)% significantly higher than that of (23.58 ± 26.13)% among NTS− ones (P = 0.004). In contrast, the difference of the PRs of VEGF between NTS+ and NTS− samples is not significant, which is (46.36 ± 32.95)% vs. (32.55 ± 29.19)% (P = 0.167). However, the expression of VEGF is significantly higher in NTS+IL-8+ HCC samples compared to the others, which is (53.00 ± 30.27)% vs. (31.02 ± 28.92)% (P = 0.020). Simultaneously, increased infiltration of CD68+ TAMs was observed in NTS+IL-8+ HCC samples (Fig. 6F). These results implied that dysfunctional activation of the NTS/IL-8 pathway was prone to induce secretion of multiple inflammatory cytokines and recruit CD68+ TAMs that promote development of inflammatory microenvironment in HCC.

Furthermore, three EMT markers, including E-Cadherin, β-Catenin and Vimentin were studied to evaluate the EMT status in NTS+IL-8+ co-expressing HCC tissues. The characteristic features of EMT was found among NTS+IL-8+ HCC samples, including loss of membrane expression of E-Cadherin (Fig. 7A) and increased cytoplasmic accumulation of β-catenin and Vimentin (Fig. 7B-C). Statistical analysis showed that the expression of E-Cadherin and β-catenin significantly correlated with the level of IL-8 in HCC tissues.

**Table 2.** The correlation between the co-expression of NTS and IL-8 in 64 cases of HCC tissues and multiple clinical-pathological features of the corresponding patients.

| Clinic-pathological features | Case | Expression of NTS | P value | Co-expression of NTS and IL-8 | P value |
|------------------------------|------|-------------------|---------|-----------------------------|---------|
| Gender                       |      |                   |         |                             |         |
| Female                       | 6    | 6                 | 0       | 0.241                       | 0.268   |
| Male                         | 58   | 47                | 11      | 48                          | 10      |
| Age                          |      |                   |         |                             |         |
| <54.44 y                     | 35   | 29                | 6       | 0.992                       | 0.746   |
| ≥54.44 y                     | 29   | 24                | 5       | 24                          | 5       |
| HBV infection                |      |                   |         |                             |         |
| No                           | 16   | 14                | 2       | 0.566                       | 0.691   |
| Yes                          | 48   | 39                | 9       | 40                          | 8       |
| Alcohol history              |      |                   |         |                             |         |
| No                           | 33   | 28                | 5       | 0.656                       | 0.914   |
| Yes                          | 31   | 25                | 6       | 26                          | 5       |
| Smoke history                |      |                   |         |                             |         |
| No                           | 26   | 22                | 4       | 0.752                       | 0.456   |
| Yes                          | 38   | 31                | 7       | 31                          | 7       |
| Clinical stage of disease    |      |                   |         |                             |         |
| I                            | 8    | 6                 | 2       | 0.805                       | 0.681   |
| II                           | 45   | 38                | 7       | 39                          | 6       |
| III                          | 11   | 9                 | 2       | 9                           | 2       |
| Clinical outcome             |      |                   |         |                             |         |
| Alive                        | 45   | 40                | 5       | 0.047                       | 0.022   |
| Dead                         | 19   | 13                | 6       | 13                          | 6       |

Note: -:- low expression of NTS or negative co-expression of NTS and IL-8 in cancer tissues; +:+ high expression of NTS or positive co-expression of NTS and IL-8 in cancer tissues.
doi:10.1371/journal.pone.0056069.t002
samples (Rcad = 0.299, Pcad = 0.002 for E-Cadherin; Rcat = 0.247, Pcat = 0.020 for β-catenin) which implied that up-regulated expression of IL-8 after dysfunctional activation of the NTS/IL-8 pathway might promote EMT in HCC cells.

Synchronous Increase of NTS and IL-8 in HCC Correlates with Worse Aprognosis and Shorter Survival of Patients after Surgery

We compared the expression analysis of NTS among patients with different gender, age, status of HBV infection, history of alcohol and smoke, disease stage, and clinical outcome. The levels of NTS expression didn’t vary significantly between male and female, elder and younger, HBV infected and uninfected patients. Besides that, no significance was identified between patients with and without history of alcohol consumption or smoke. But it’s evident that the expression levels of NTS correlated with the clinical outcomes although they didn’t vary significantly among HCC samples at different clinical stage. It was observed that near one third of HCC patients who passed away had NTS-overexpressing tumors, which is significantly higher than the percentage in alive HCC patients (31.58% vs. 11.11%, P = 0.047, Table 2). We further compared the clinical outcome of the patients co-expressing NTS and IL-8 with the others, and found 60% (6/10) of HCC patients bearing NTS + IL-8 + tumors died after the surgery, which is about 2.5 folds of the incidence risk of 24.07% (13/54) in the other patients (P = 0.022). This result implied that the co-expression of NTS and IL-8 might be a valuable predictive factor for HCC prognosis.

Therefore, the univariate survival analysis between different clinical and pathological parameters and OS of HCC patients was performed using the Kaplan-Meier method and the log-rank test. A-C). None significant difference of OS was observed between patients with and without history of alcohol consumption (A) or HBV infection (B), and patients at different clinical stages (C). D-J). The relationship between the OS and the expression levels of NTS(D), IL-8(E), MMP-9(H), VEGF(I) and CD68(J) was studied. The univariate survival analysis showed that the expression level of NTS exclusively adversely affected the OS of HCC patients (D), in which the patients bearing NTS + tumors suffered from shorter OS than those bearing NTS - tumors (P = 0.035). The same result was obtained in the patients bearing NTS + IL-8 + tumors (F) whose OS are 3 folds shorter than the others (P = 0.011). Note: 0: Negative/low expression of certain markers in cancer tissues; 1: Positive expression of certain markers in cancer tissues.

doi:10.1371/journal.pone.0056069.g008

Figure 8. Synchronous increase of NTS and IL-8 in HCC correlated with worse prognosis and shorten survival of patients after surgery. The univariate survival analysis between different clinical and pathological parameters of 64 cases of HCC patients was performed using the Kaplan-Meier method and the log-rank test. A-C). None significant difference of OS was observed between patients with and without history of alcohol consumption (A) or HBV infection (B), and patients at different clinical stages (C). D-J). The relationship between the OS and the expression levels of NTS (D), IL-8 (E), MMP-9 (H), VEGF (I) and CD68 (J) was studied. The univariate survival analysis showed that the expression level of NTS exclusively adversely affected the OS of HCC patients (D), in which the patients bearing NTS + tumors suffered from shorter OS than those bearing NTS - tumors (P = 0.035). The same result was obtained in the patients bearing NTS + IL-8 + tumors (F) whose OS are 3 folds shorter than the others (P = 0.011). Note: 0: Negative/low expression of certain markers in cancer tissues; 1: Positive expression of certain markers in cancer tissues.

doi:10.1371/journal.pone.0056069.g008
As shown in Fig. 8, no significant difference of OS was observed between patients with different gender, age, status of HBV infection, history of alcohol consumption or clinical stages (Fig. 8A–C). Next, we evaluated the relationship between the OS and the expression levels of NTS, IL-8, MMP-9, VEGF and CD68 (Fig. 8D–F). The univariate survival analysis showed that the expression level of NTS exclusively executed significant influence on the OS of HCC patients, in which the NTS+ HCC patients suffered from shorter OS than the NTS− HCC patients (P = 0.035, Fig. 8D). The same result was observed in the patients bearing NTS+/IL-8+ tumors whose OS are 3 folds shorter than the others (P = 0.011, Fig. 8F). In order to distinguish the independent predictive factors of OS, the multivariate COX regression analysis was performed. It’s demonstrated that the co-expression of NTS and IL-8 in cancer tissues is an independent prognostic factor to predict the OS of HCC patients. Compared to the HCC patients without co-expression of NTS and IL-8, the OS of NTS+/IL-8+ HCC patients significantly decreased (24.65 ± 4.45 m vs. 75.79 ± 16.32 m, P = 0.013), and these patients are under a higher hazard of death at an expected hazard ratio (HR) of 3.457.

Discussion and Conclusions

Chronic inflammation has been recognized as a pivotal pathological factor in the development of hepatitis-related HCC. But the role of ongoing inflammation in disease progression has not yet been elucidated. Some studies have demonstrated that the metastatic potential of HCC is influenced by the local inflammatory microenvironment, in which the pro-inflammatory peritumoral cytokine milieu and increased infiltration of neutrophils in the stroma may play significant roles in promoting the metastatic spread of HCC [27,28]. However, our understanding of the key molecular mechanisms and predominant signaling pathways that regulate this pathological process is limited. Utilization of high-density nucleic acid microarrays is one of the most effective approaches to identifying these key molecular events. In this study, we used the GeneChip Human Genome U133 plus 2.0 arrays and identified a specific subgroup of HCC displaying significantly enhanced inflammatory properties in which up-regulated expression of NTS was revealed as the characteristic molecular phenotype. In order to corroborate this result, three public expression profiling data sets from GEO were utilized and integrated into our in-house data to repeat the comprehensive bioinformatics analysis. Accordingly, a specific subgroup of HCC displaying significantly activated inflammation-related pathways and up-regulated NTS expression was observed, accompanied by activation of two well-known invasion-related pathways: HIF-1α signaling and Wnt/β-catenin signaling. Therefore, our results implied that NTS might represent a key protein biomarker to induce and maintain an inflammatory tumor microenvironment and promote tumor invasion and metastasis in a certain subgroup of HCC.

NTS is a 13 amino acid neuropeptide first isolated from the bovine hypothalamus by Carraway et al. in 1973 [29]. NTS is widely expressed in the brain and gastrointestinal tract of humans and animals. As a neuroendocrine peptide, NTS has significant interaction with the dopaminergic system and plays an important role in lowering blood pressure and regulating gastrointestinal functions [23]. In recent years, some studies have demonstrated that NTS can provide a growth signal to multiple types of epithelial-derived malignancies including colon cancer, pancreatic cancer, breast cancer, lung cancer, prostate cancer and head and neck cancers [26,30–32]. The engagement of the high affinity receptor NTR1 with NTS lead to the activation of the phosphoinositide and adenyl cyclase pathways which directly stimulate the proliferation, migration and invasion of various cancers cells and facilitates cancer growth [33]. In addition, multiple downstream signaling pathways are activated after interaction of NTS and NTR1, including the mitogen-activated protein kinases (MAPKs), extracellular-signal-regulated kinases (ERK), c-Jun N-terminal kinases (JNK), RhoGTPase and NFκB, resulting in the expression of a number of inflammation-related genes, such as IL-8 in certain solid tumors like colorectal cancer, pancreatic cancer, prostate cancer and head and neck cancer etc. [34]. Carraway et al. [35] speculated that NTS induced IL-8 secretion after activation of the NTS/IL-8 pathway resulted in the formation of an inflammatory microenvironment, which was confirmed by subsequent studies in colon cancer where an activated NTS signaling pathway definitely aggravated local inflammation and promoted EMT of cancer cells via TGF-β signaling [36]. IL-8 (CXCL8), a pro-inflammatory cytokine secreted by cancer cells and macrophages and a chemotactic factor for leukocytes, is reported to promote tumor invasion, progression and angiogenesis in multiple solid tumors, including colorectal cancer, prostate cancer, breast cancer, colon cancer, pancreatic cancer, ovarian cancer and bladder cancer [24]. The biological effects of IL-8 are mediated through the binding of IL-8 to CXCR1 and CXCR2, two G protein-coupled receptors (GPCRs) expressed on cancer cells, endothelial cells, neutrophils and TAMs. Intratumoral IL-8 expression is proposed to be a key regulator enhancing angiogenesis [37] and infiltration of neutrophils and TAMs in situ [38]. It also increases proliferation, migration and invasion capacity of tumor cells [39–41] and maintains self-renewal and survival of cancer stem cells [42] which favors the generation of a metastasis-prone microenvironment. Thus, inhibiting the expression of IL-8 in tumor cells by blocking NTS stimulation has been accepted to represent an effective intervention strategy of anti-cancer therapy in colorectal cancer [43]. Therefore, we proposed that over-expression of NTS in HCC induces the development of inflammation and promotes tumor invasion by inducing the secretion of IL-8 via the NTS/IL-8 pathway.

NTS is frequently expressed in the gastrointestinal tract but rarely detected in HCC. Normally, NTS is transiently expressed in fetal liver and disappears from normal mature liver and most of primary HCC tissues [44]. In our study, IHC results demonstrated that the NTS protein is predominantly expressed on the membrane and in the cytoplasm of cancer cells rather than stromal cells, implying that apparent ectopic expression of NTS exists in some HCC samples. Accordingly, Tang et al. reported recently that up-regulated NTS expression was detected in some HCC cell lines [45] which induced secretion of IL-8 and promoted CD133+ liver tumor-initiating cells (TICs) exhibiting a greater ability to self-renew. Consistently, both our microarray data and IHC results demonstrated that the expression of NTS both at RNA level and protein level is positively correlated with IL-8, suggesting that the NTS/IL-8 pathway is abnormally activated in some HCC samples.

In order to determine if the activation of NTS/IL-8 pathway in HCC induces the inflammatory microenvironment as previously observed in colorectal cancer, the expression of predominant downstream inflammation-related biomarkers, such as VEGF and MMP9, and infiltration of inflammatory leukocytes (TAMs) were detected in high NTS-expressing HCC samples. We demonstrated that the expression levels of VEGF and MMP9 were significantly correlated with co-expression of NTS and IL-8 in HCC. Similarly, increased infiltration of CD68+ TAMs was observed in NTS+IL-8+ samples, which implied that activation of NTS/IL-8 is prone to
promote the development of an inflammatory microenvironment in HCC.

Furthermore, since intratumoral IL-8 expression is reported to increase the invasive potential of tumor cells, we compared the features of EMT between high and low NTS-expressing HCC samples. EMT is a biological process that allows a polarized epithelial cell to undergo multiple biochemical changes that enable it to assume a mesenchymal phenotype, which has been confirmed as an important molecular basis for the recurrence and metastasis of epithelial-derived cancers [46–48]. As the characteristic features of EMT, lost expression of E-Cadherin on the membrane and increase in β-catenin and vimentin in the cytoplasm were exclusively observed in NTS+IL-8+ HCC samples which implied that dysfunctional activation of NTS/IL-8 pathway promote the development of an invasive phenotype in HCC cells. Further survival analysis demonstrated that the co-expression of NTS and IL-8 in HCC significantly correlated with worse prognosis and shorter survival of patients after surgery, suggesting that dysfunctional activation of the NTS/IL-8 pathway significantly promote progression of disease and adversely affects prognosis of HCC patients after surgery.

Thus, our results point out that the dysfunctional activation of a specific NTS/IL-8 pathway in a certain subgroup of HCC could be responsible for worse outcomes by promoting the development of a local inflammatory microenvironment and increasing the invasive potential of tumor cells which might be proposed as a promising therapeutic target and a predictive biomarker for HCC diagnosis and treatment.

Acknowledgments

We thank Dr. Fang Yan, Department of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University School of Medicine, Nashville, and Dr. Shizhen Emily Wang, Division of Tumor Cell Biology, Beckman Research Institute of City of Hope for their help and assistance in preparation of this paper. We thank TeriNe Caasneuf and Karin Verstraeten from Janssen Research and Development, a Division of Janssen Pharmaceutica NV, for their help in gene expression profiling and bioinformatics data analysis.

Author Contributions

Conceived and designed the experiments: JY. Performed the experiments: JY PL XW HW. Analyzed the data: JY YC. Contributed reagents/materials/analysis tools: XR HL GY KC. Wrote the paper: JY XH.

References

1. Bray F, Jemal A, Glyn N, Ferlay J, Forman D (2012) Global cancer transitions according to the Human Development Index (2008–2008): a population-based study. Lancet Oncol 13: 790–801.
2. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860–867.
3. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331: 1560–1567.
4. Sieven KS, Kuttan G (2009) Role of macrophages in tumour progression. Immunol Lett 123: 97–102.
5. Liu Q, Zhang C, Sun A, Zheng Y, Wang L, et al. (2009) Tumor-educated CD11bhighIαlow regulatory dendritic cells suppress T cell response through arginase I. J Immunol 182: 6207–6216.
6. Peng HH, Liang S, Henderson AJ, Dong C (2007) Regulation of interleukin-8 expression in melanoma-stimulated neutrophil inflammatory response. Exp Cell Res 313: 551–559.
7. Grivellet E, Nico R, Ribatti D (2008) Mast cells and tumour angiogenesis: new insight from experimental carcinogenesis. Cancer Lett 269: 1–6.
8. Yang JD, Nakamura I, Roberts LR (2011) The tumor microenvironment in hepatocellular carcinoma: Current status and therapeutic targets. Semin Cancer Biol 21: 33–43.
9. Labbozetta M, Notarbarolo M, Poma P, Giannitrapani L, Cervello M, et al. (2006) Significance of autologous interleukin-6 production in the HA22T/VGH cell model of hepatocellular carcinoma. Ann N Y Acad Sci 1089: 268–275.
10. Young KE, Alford SC, Jones R, Asjla P, Qin S, et al. (1999) Expression and function of CXCL8 and CC chemokines in human malignant liver tumors: a role for human monokine induced by gamma-interferon in lymphocyte recruitment to hepatocellular carcinoma. Hepatology 30: 100–111.
11. van Molenstein H, van Pol J, Vreeswijk C (2011) Molecular classification of hepatocellular carcinoma anual 2011. Eur J Cancer 47: 1789–1797.
12. Andrisani OM, Studach L, Merle P (2011) Gene signatures in hepatocellular carcinoma (HCC). Semin Cancer Biol 21: 4–9.
13. Iguni N, Hamamoto Y, Tsunedomi R, Oka M (2008) Tumor-educated macrophages systems for outcome prediction of hepatocellular carcinoma. Cancer Sci 99: 659–665.
14. Huynh H, Chow PK, Palanisamy N, Salto-Tellez M, Goh BC, et al. (2008) Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Hepatol 49: 52–60.
15. Liao YL, Sun YM, Chau GY, Chau YP, Lai TC, et al. (2008) Identification of SOX4 target genes using phylogenetic footprinting-based prediction from transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Research 36: e175.
16. Talloen W, Clevert DA, Hocherter S, Amaranthus D, Bijjens L, et al. (2007) IV-NT-calls for the exclusion of non-informative genes: a highly effective filtering tool for microarray data. Bioinformatics 23: 2897–2902.
17. Wouters I, Gohlmann HW, Bijjens L, Kass SU, Molenberghs G, et al. (2003) Graphical exploration of gene expression data: a comparative study of three multivariate methods. Biometrics 59: 1131–1139.
18. Smyth GK (2005) Limma: linear models for microarray data. In: Gentleman R, Carey V, Dudot S, Irizarry R, Huber W, editors. Bioinformatics and Computational Biology Solutions using R and Bioconductor. Springer, New York. 397–420.
19. Gohmann H, Talloen W (2009) Gene Expression Studies Using Affymetrix Microarrays. Chapman & Hall, New York. 148 p.
20. Thomas S, Bouchet D (2010) A survey of current software for network analysis in molecular biology. Hum Genomics 4: 353–360.
21. Olszewski U, Hamilton G (2009) Neurotensin signaling induces intracellular alkalinization and interleukin-8 expression in human pancreatic cancer cells. Mol Oncol 3: 204–213.
22. Shimizu S, Tsokada J, Sugimoto T, Kikkawa N, Sasaki K, et al. (2006) Identification of a novel therapeutic target for head and neck squamous cell carcinomas: a role for the neurotensin-neurotensin receptor 1 oncogenic signaling pathway. Int J Cancer 123: 1816–1823.
23. Budhi A, Forges M, Ye QH, Jia HL, He P, et al. (2006) Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10: 99–111.
24. Kuang DM, Zhao Q, Wu Y, Peng C, Wang J, et al. (2011) Peritumoral neutrophil link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol. 54: 948–955.
25. Carraway RE, Plona AM (2006) Involvement of neurotensin in cancer growth: an update. Neurotensin receptors. ACS Chem Biol 4: 503–525.
26. Myers RM, Shearman JW, Kitching MO, Ramos-Montoya A, Neal DE, et al. (2009) Neurotensin receptor 1 gene activation by the Tcf/beta-catenin pathway is an early event in human colon adenocarcinomas. Cancer Genet 227: 708–716.
27. Mijatovic T, Gailly P, Mathieu V, De Neve N, Yeaton P, et al. (2007) Neurotensin is a versatile modulator of in vitro human pancreatic ductal adenocarcinoma cell (PDAC) migration. Cell Oncol 29: 315–326.
28. Amorini GP, Deehle PD, Parsons SJ (2007) Neurotensin stimulates mitogenesis of prostate cancer cells through a novel c-Src/Stat3b pathway. Oncogene 26: 743–756.
29. Myers RM, Shearman JW, Kitching MO, Ramos-Montoya A, Neal DE, et al. (2009) Cancer, chemistry, and the cell: molecules that interact with the neurotensin receptors. ACS Chem Biol 4: 503–525.
30. Wang X, Jackson LN, Johnson SM, Wang Q, Evers BM (2010) Suppression of neurotensin receptor type 1 expression and function by histone deacetylase inhibitors in human colorectal cancers. Mol Cancer Ther 9: 2389–2398.
31. Carraway RE, Plona AM (2006) Involvement of neurotensin in cancer growth: evidence, mechanisms and development of diagnostic tools. Peptides. 27: 2445–2456.
37. Li A, Dubey S, Varney ML, Dave BJ, Singh RK (2003) IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 170: 3369–3376.

38. De Larco JE, Wurtz BR, Furcht LT (2004) The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res 10: 4895–4900.

39. Yao C, Lin Y, Chua MS, Ye CS, Bi J, et al. (2007) Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells. Int J Cancer 121: 1949–1957.

40. Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, et al. (2007) Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res 67: 6854–6862.

41. Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C (2011) CXCR1 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res 71: 5296–5306.

42. Gneozi C, Liu S, Diebel ME, Korkaya H, Lao M, et al. (2010) CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 120: 485–497.

43. Zhao D, Keates AC, Kulunt-Moore S, Meyer MP, Kelly CP, et al. (2001) Signal transduction pathways mediating neurotensin-stimulated interleukin-8 expression in human colonocytes. J Biol Chem 276: 44464–44471.

44. Reubi JC, Waser B, Schaar JC, Lainue JA (1999) Neurotensin receptors in human neoplasms: high incidence in Ewing’s sarcomas. Int J Cancer 82: 213–219.

45. Tang KH, Ma S, Lee TK, Chan YP, Kwan PS, et al. (2012) CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology 55: 807–820.

46. Ding W, You H, Dang H, LeBlanc F, Galicia V, et al. (2010) Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion. Hepatology 52: 945–953.

47. Thiery JP (2003) Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15: 740–746.

48. van Zijl F, Zulehner G, Petz M, Schneller D, Kornauth C, et al. (2009) Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol 5: 1169–1179.